About Us
Our Company
Management & Board
Aceragen
Tilsotolimod
Toll-Like Receptor Activation
Publications & Presentations
Investor Relations
×
Local treatment with novel TLR9 agonist IMO-2125 demonstrates antitumor activity in preclinical models of pancreatic cancer
